264 related articles for article (PubMed ID: 32906621)
1. Therapeutic Strategies Targeting DUX4 in FSHD.
Le Gall L; Sidlauskaite E; Mariot V; Dumonceaux J
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906621
[TBL] [Abstract][Full Text] [Related]
2. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
Banerji CRS; Zammit PS
EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
[TBL] [Abstract][Full Text] [Related]
3. Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).
Ansseau E; Vanderplanck C; Wauters A; Harper SQ; Coppée F; Belayew A
Genes (Basel); 2017 Mar; 8(3):. PubMed ID: 28273791
[TBL] [Abstract][Full Text] [Related]
4. DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy.
Thijssen PE; Balog J; Yao Z; Pham TP; Tawil R; Tapscott SJ; Van der Maarel SM
Skelet Muscle; 2014; 4():19. PubMed ID: 25789155
[TBL] [Abstract][Full Text] [Related]
5.
Sidlauskaite E; Le Gall L; Mariot V; Dumonceaux J
J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32731450
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
7. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.
Wallace LM; Garwick SE; Mei W; Belayew A; Coppee F; Ladner KJ; Guttridge D; Yang J; Harper SQ
Ann Neurol; 2011 Mar; 69(3):540-52. PubMed ID: 21446026
[TBL] [Abstract][Full Text] [Related]
8. Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy.
Ganassi M; Figeac N; Reynaud M; Ortuste Quiroga HP; Zammit PS
Front Cell Dev Biol; 2022; 10():802573. PubMed ID: 36158201
[TBL] [Abstract][Full Text] [Related]
9. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
10. Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.
Jones TI; King OD; Himeda CL; Homma S; Chen JC; Beermann ML; Yan C; Emerson CP; Miller JB; Wagner KR; Jones PL
Clin Epigenetics; 2015; 7(1):37. PubMed ID: 25904990
[TBL] [Abstract][Full Text] [Related]
11. Facioscapulohumeral Muscular Dystrophy.
DeSimone AM; Pakula A; Lek A; Emerson CP
Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
[TBL] [Abstract][Full Text] [Related]
12. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
13. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
Schätzl T; Kaiser L; Deigner HP
Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
[TBL] [Abstract][Full Text] [Related]
14. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
15. Cellular and animal models for facioscapulohumeral muscular dystrophy.
DeSimone AM; Cohen J; Lek M; Lek A
Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174531
[TBL] [Abstract][Full Text] [Related]
16. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
17. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
[TBL] [Abstract][Full Text] [Related]
18. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
Elife; 2015 Jan; 4():. PubMed ID: 25564732
[TBL] [Abstract][Full Text] [Related]
19. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
20. Increased DUX4 expression during muscle differentiation correlates with decreased SMCHD1 protein levels at D4Z4.
Balog J; Thijssen PE; Shadle S; Straasheijm KR; van der Vliet PJ; Krom YD; van den Boogaard ML; de Jong A; F Lemmers RJ; Tawil R; Tapscott SJ; van der Maarel SM
Epigenetics; 2015; 10(12):1133-42. PubMed ID: 26575099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]